News
MDGL
83.46
-1.41%
-1.19
BRIEF-Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 Nash Data And Multiple Oral Abstracts At Easl's International Liver Congress
reuters.com · 5h ago
Madrigal Pharmaceuticals Supports International NASH Day on June 9
Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient careCONSHOHOCKEN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pu...
GlobeNewswire · 06/06 12:00
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will pa...
GlobeNewswire · 06/02 12:00
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will par...
GlobeNewswire · 05/17 12:00
--Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $170 From $180, Maintains Outperform Rating
MT Newswires · 05/10 10:13
BRIEF-Madrigal Pharmaceuticals Inc Says On May 9, Entered Into A Loan And Security Agreement
reuters.com · 05/09 16:20
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch
Benzinga · 05/09 14:14
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/09 13:45
Madrigal Pharmaceuticals Q1 EPS $(3.36) Beats $(3.62) Estimate
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimate of $(3.62) by 7.18 percent. This is a 1.2 percent decrease over losses of $(3.32) per share
Benzinga · 05/09 10:41
Recap: Madrigal Pharmaceuticals Q1 Earnings
  Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/09 10:40
Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20
Madrigal Pharmaceuticals press release (NASDAQ:MDGL): Q1 GAAP EPS of -$3.36 beats by $0.20. As of March 31, 2022, Madrigal had cash, cash equivalents and marketable securities of $220.0 million, compared
Seekingalpha · 05/09 10:32
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
-- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q1 Loss $-3.36, vs. Street Est of $-3.54
MT Newswires · 05/09 06:44
Notable earnings before Monday's open
ACM,ADAP,APRN,AUD,AVDL,AZUL,BLDP,BNTX,BTAI,COTY,DTIL,DUK,EGRX,ELAN,ENR,FOLD,GSL,HEP,HGV,JLL,KNDI,KOS,LINC,MAC,MDGL,MRSN,MSGE,MTBC,OSG,PLTR,PRTY,RCM,RIDE,SPTN,TGNA,THS,TSN,VRTV,VTRS,WOW,WTRG For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 05/06 13:56
How To Attend Madrigal Pharmaceuticals Q1 2022 Earnings Conference Call
  Madrigal Pharmaceuticals (NASDAQ:MDGL) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Benzinga · 05/04 14:10
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financi...
GlobeNewswire · 04/28 12:00
10 Best Stocks to Buy Now According to Billionaire Nicholas Pritzker’s Tao Capital
In this article, we discuss 10 best stocks to buy now according to billionaire Nicholas Pritzker’s Tao Capital. If you want to see some more favorite stocks of the billionaire, click 5 Best Stocks to Buy Now According to Billionaire Nicholas Pritzker’s Tao...
Insider Monkey · 04/12 21:37
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will p...
GlobeNewswire · 03/09 21:30
Madrigal Pharmaceuticals Q4 net loss widens Y/Y
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The company
Seekingalpha · 02/24 14:48
Madrigal Posts Narrower Q4 Loss
MT Newswires · 02/24 10:07
More
Webull provides a variety of real-time MDGL stock news. You can receive the latest news about Madrigal Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).